A look at Celgene
Headquartered in Summit, New Jersey, Celgene (CELG) is one of the leading biopharmaceutical companies. Its product portfolio includes drugs for the treatment of cancer as well as inflammatory diseases.
The above chart shows the revenues and EPS (earnings per share) for Celgene over the last eight quarters and estimates for 3Q17.
Celgene stock has risen ~12.3% in 3Q17. It has risen ~17.5% year-to-date as of October 20, 2017.
Wall Street analysts estimate that the stock has the potential to rise ~11.6% over the next 12 months. Their recommendations show a 12-month target price of $151.68 per share compared to the last price of $135.96 per share as of October 19, 2017.
There are 28 analysts tracking Celgene stock. Twenty-three of them recommend a “buy,” three recommend a “hold,” and two recommend a “sell.” The consensus rating for Celgene stands at 1.79, which represents a “strong buy” for both momentum investors and long-term growth investors.
Analysts’ revenue estimates
Celgene’s revenues are mainly driven by the strong performances of its key products Revlimid, Pomalyst, Vidaza, and others.
Wall Street analysts estimate revenues of $3.4 billion in 3Q17, a ~14.4% rise compared to 3Q16, and EPS of $1.78.
To divest the company-specific risks, investors can consider ETFs such as the iShares Global Healthcare (IXJ), which holds 2.4% of its total assets in Celgene (CELG). IXJ also holds 2.5% in Sanofi (SNY), 3.8% in Merck & Co. (MRK), and 2.4% in Gilead Sciences (GILD).